• Skip to main content
  • Skip to footer

GBT Pharma

Experts in OTC market access

  • Our Services
    • International Business Development
    • International Product Development
  • Our Products
    • cannaQIX
    • Klear-vol
    • Estroplus Meno Manage
    • Pediatra Suizo
    • Estroplus™
    • Phytovir®
    • Similasan®
    • Kwai
    • Kira
  • About GBT Pharma
    • Company History
  • GBT Pharma Clients
  • The GBT Pharma Team
    • Our Team in Switzerland
    • Our Team in Latin America
    • Our Team in the UK
  • News
  • Contact Us

May 2, 2017 By Heather Scott

Brand heritage is key to an OTC relaunch

A strong brand heritage, a more attractive product and smarter marketing is driving the success of the Similasan eye-care brand following its recent relaunch into the Netherlands, according to Harm-Jan Schuurman, head of the Swiss homoeopathic firm’s Dutch subsidiary.

Speaking exclusively to OTC bulletin, Schuurman pointed out that the firm had combined these three elements to establish itself as a top-five player in the eye-care category with a 10% share, following the return of its Similasan Oogdruppels Nr.1 and Nr.2 eye drops to the Dutch market in 2014 after a two-year absence.

Filed Under: News

Footer

Contact Us

Rte de la Vignettaz 25 |

1700 Fribourg |

Switzerland |

Tel: + 41 79 262 60 43

gian.trepp@gbtpharma.com

About Us

We specialize in developing international markets for our clients. As your partner in driving international growth, GBT Pharma works to quickly understand your business and its objectives.

Follow Us

  • LinkedIn

Copyright © 2025 · GBT Pharma